Post-infectious Autoimmune Cardiac Risk Index (Autoantibodies Panel)
Autoantibody panel inputs
Enter each result on the same prespecified 0–5 normalized research scale.
Enter all six values
The index is displayed only after all fields contain valid values from 0 to 5.
Method and interpretation
The original code specifies a weighted sum of six antibody inputs and converts the result to a 0–100 display. The arithmetic weights are retained for exploratory use only; they do not establish clinical validity.
| Marker | Weight in original code |
|---|---|
| Anti-Myosin Antibody (AMA) | 25% |
| Anti-Troponin I Antibody (ATIA) | 20% |
| β1-Adrenergic Receptor Antibody | 20% |
| M2 Muscarinic Receptor Antibody | 15% |
| Cardiac Myosin Heavy Chain Antibody | 10% |
| Anti-Endothelial Cell Antibody (AECA) | 10% |
Calculation retained from source code
Index = 20 × [0.25(AMA) + 0.20(ATIA) + 0.20(β1AR-Ab) + 0.15(M2R-Ab) + 0.10(MHC-Ab) + 0.10(AECA)], assuming every input has first been normalized to a 0–5 scale. Under that assumption, the mathematical output ranges from 0 to 100.
What the value means
- A higher result means only that the entered normalized values produce a higher weighted arithmetic index.
- It is not a validated probability of autoimmune cardiac disease, myocarditis, or dilated cardiomyopathy.
- The input scale, coefficients, and 0–100 transformation are not clinically validated by the cited references.
- No low/moderate/high/very-high category is shown because the original cutoffs lack a verified derivation study.
Clinical context and limitations
Cardiac autoantibodies have been investigated in selected immune-mediated cardiac conditions, but findings depend on the antibody, assay method, population, and clinical context. Evidence about individual autoantibodies does not validate this six-marker composite.
Clinical assessment
When myocarditis or an inflammatory myocardial syndrome is suspected, evaluation should follow established diagnostic pathways and the clinical presentation. Depending on the case, this may include ECG, cardiac biomarkers, echocardiography, cardiac magnetic resonance, and selected endomyocardial biopsy or other investigations.
Before research use
- Define each assay, units, reference range, and normalization method in advance.
- Provide a derivation dataset and justify each coefficient statistically and biologically.
- Evaluate discrimination, calibration, external validation, and clinical utility before proposing cutoffs.
- Do not use this exploratory index to direct diagnosis or treatment.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.